ArticleNature2025
Tumour-wide RNA splicing aberrations generate actionable public neoantigens.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Bioengineering strategies for improving the immunogenicity of mRNA vaccines.Signal transduction and targeted therapy · 2026Review
- Abundant CD8British journal of cancer · 2026Article
- Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.MedScience · 2026Review
- Changes in Alternative Splicing are Associated with Insecticide Response and Resistance.Genome biology and evolution · 2026Article
- DRIVE: a comprehensive resource deciphering drug-induced transcriptomic and splicing response in cancer cell.Neoplasia (New York, N.Y.) · 2026Article
- PRMT5-mediated intron retention triggers innate and adaptive immunity against cancer.EMBO molecular medicine · 2026Article
- Review
- Review
- Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Loss of IL10 Signaling Promotes TLR9-Driven Liver Dysfunction by Allowing T Cell Receptor-Mediated T Cell Activation.Research square · 2026Article
- Harnessing Tumor-Specific Transcript Diversity Uncovers a Shared Neoantigen Reservoir for Pancreatic Ductal Adenocarcinoma.MedComm · 2026Article
- The splice of life: an isoform-centric view of disease, technology, and therapeutics.The Journal of clinical investigation · 2026Review
- Splicing-driven post-translational dysregulation: a new frontier for precision cancer medicine and immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Article
- DeepSAP: improved RNA-seq alignment by integrating transcriptome guidance with transformer-based splice junction scoring.Genome biology · 2026Article
- RNA-binding proteins and ribonucleoproteins as determinants of immunity.Nature reviews. Immunology · 2026Review
- A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Neoantigen Targeting as a Novel Approach for Therapy-Resistant Tumors.Molecular diagnosis & therapy · 2026Review
- Review
- Mapping glioblastoma's isoform diversity using long-read single-cell analysis.Nature communications · 2026Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
31 authors.
Darwin W KwokDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Nicholas O SteversDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-1082-6423
Iñaki EtxeberriaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2713-0836
Takahide NejoDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9191-8823
Maggie Colton CoveDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-7635-3748
Lee H ChenDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Jangham JungDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Kaori OkadaDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Senthilnath LakshmanachettyDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Marco GallusDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Abhilash BarpandaDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
Chibo HongDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Gary K L ChanDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Jerry LiuDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Samuel H WuDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Emilio RamosDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
Akane YamamichiDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Payal B WatchmakerDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Hirokazu OginoDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-2446-8789
Atsuro SaijoDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-7710-5498
Aidan DuDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Nadia R GrishaninaDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
James WooDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Aaron DiazDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-9059-9501
Shawn L Hervey-JumperDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Susan M ChangDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Joanna J PhillipsDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3789-8120
Arun P WiitaDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-7465-6964
Christopher A KlebanoffHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. klebanoc@mskcc.org.ORCID 0000-0001-9645-3896
Joseph F CostelloDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA. joseph.costello@ucsf.edu.ORCID 0000-0003-3189-584X
Hideho OkadaDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA. hideho.okada@ucsf.edu.ORCID 0000-0003-0076-9920
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MTissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4MProject 4: Multi-modality Metabolic Imaging for Monitoring Molecular Sub-types of GliomaP01CA118816 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Susan M Chang, Janine Marie Lupo · 2007 to 2026
$44.7MTargeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Marc Ladanyi · 2018 to 2026
$21.5MTraining Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6MPREDOCTORAL TRAINING IN BIOMEDICAL SCIENCEST32GM008568 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANSEL, KARL MARK · 1995 to 2019
$6.3MPreclinical development of breakthrough immunotherapy for brain tumorsR35NS105068 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKADA, HIDEHO · 2018 to 2025
$6.0MMolecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.R37CA259177 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christopher Austin Klebanoff · 2021 to 2026
$3.1M3-D spatial approach to discover genomic effectors of immunosuppression during malignant transformationR01CA244838 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COSTELLO, JOSEPH F · 2020 to 2024
$2.7MTOX-driven CD8 T cell differentiation and dysfunction in tumorsR01CA269733 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Andrea Schietinger · 2023 to 2026
$2.4MGlioma immunotherapy targeting IDH mutation-derived epitope and immunosuppressionR01CA222965 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKADA, HIDEHO · 2018 to 2022
$1.8MNovel cell therapy approaches for molecularly defined subsets of therapy-resistant melanomaR01CA286507 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christopher Austin Klebanoff · 2023 to 2026
$1.8MNCI NIH HHS P01 CA118816NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA097257NCI NIH HHS P50 CA217694NCI NIH HHS R01 CA222965NCI NIH HHS R01 CA244838NCI NIH HHS R01 CA269733NCI NIH HHS R01 CA286507NCI NIH HHS R37 CA259177NCI NIH HHS R50 CA274229NCI NIH HHS T32 CA151022NIGMS NIH HHS T32 GM008568NIH HHS S10 OD028511NINDS NIH HHS R35 NS105068
Abstract
T cell-based immunotherapies hold promise in treating cancer by leveraging the immune system's recognition of cancer-specific antigens
Indexed as
Antigens, NeoplasmNeoplasmsRNA SplicingAnimalsCD8-Positive T-LymphocytesClone CellsFemaleHumansImmunotherapyMaleMiceReceptors, Antigen, T-CellAntigens, NeoplasmReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.